Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Commentary

Commentary: COVID-19 and diabetes

Carmen V. Villabona

ARTICLE INFO

Article history:
Received 25 March 2020
Accepted 31 March 2020
Available online 6 April 2020

This is a comment on the recent work published by Wang et al.: the first report compiling epidemiologic data from COVID 19 and Diabetes [1]. As we understand there is an urgent need to publish the facts and statistics of this everyday changing pandemic and in an effort to reporting and informing the medical community real-time, erroneous conclusions might be generated. Consequently, the public and healthcare providers might have wrong assumptions and misleading interpretations. In this commentary, we highlight some of the limitations and flaws we identified and thereafter, we summarize what we already know from previous published data on diabetes and sepsis. This communication should also serve as call for expedited well-designed epidemiologic and interventional studies, only then, factual conclusions could be drawn.

The first problem we find on this report is that conclusions are driven from small cohorts. The denominator is 1102 when he mentions incidence of diabetes (7.3%). When he reports mortality in patients with no diabetes (0.9%) the denominator is 15,536, this is a much larger cohort. We would need to know the exact prevalence of diabetes in the largest cohort to make a more precise comparison. Besides that, when the report compares how many patients required care in the ICU ( Intensive Care Unit) vs. how many patients did not require care in ICU care, the denominator of cohort is even smaller:138.

There is a chronological factor skewing the numbers compared with current status, the number of cases reported at the current moment (March 22nd, 2020) worldwide is 311,988, 13,407 deaths and 93,790 recovered cases, the report is from February 24th 2020, when the virus had caused a total of 79,331 confirmed cases and 2618 deaths.

These data is not valid to draw conclusions, it might be a “trend” however we cannot draw a valid conclusion.

Other observation we encounter is that the studied Asian population differs from the heterogeneous population in the United States, presentations and outcomes might differ given these different populations.

Another limitation we identify is the lack of clinical information to be able to perform risk stratification within the diabetic population. We do not have information about diabetes duration, time of diagnoses; at times, patients newly diagnosed with diabetes have stress-induced hyperglycemia, those patients, based on previous data, have the poorest outcomes when they become septic. In this report the type of diabetes is not specified, we know Type 1 and Type 2 Diabetes are very different entities. Clinical characteristics at baseline are not presented including medications and comorbidities.

Either diabetes control prior to admission was not mentioned neither glycemc control, treatment and management in the inpatient setting (i.e implementation of insulin protocols or availability of an inpatient diabetes team)

Lastly, and in my opinion, a very important factor to mention and probably one of the main factors driving morbidity and mortality would be the availability of appropriate resources at the time of each patient’ hospitalization, Was the healthcare system already saturated and overwhelmed?
In the next paragraph I would focus in what we really know and what we don’t know about “Diabetes and Infection” I will point out statements and facts based on previous literature [2–17]

1. There is preclinical data in animal models proven a dysfunction of the immune system (humoral and cellular) and there is an abnormal inflammatory state in patients with diabetes and/or hyperglycemia. There is an increased susceptibility for patients with diabetes to have an infection.

2. Hyperglycemia is an important factor for patients with diabetes that influence sepsis incidence and course.

3. Hyperglycemia is also and important prognostic factor when patients have sepsis and do not have diabetes.

4. We do not know if certain medications worsen or improve these outcomes with the exception of insulin. Insulin therapy has been demonstrated in previous data to decrease inflammation, on the other hand clinical studies have found that too intense glycemic control is detrimental to our patients in the ICU, especially in patients in medical ICUs compared with patients in Surgical ICU units.

5. Hypoglycemia is detrimental to critically ill patients

6. Hypoglycemia is a negative prognostic factor for critical ill patients

Finally we draw the conclusion we need well-designed epidemiological and interventional studies with appropriate methodology and design to appropriately identify risk factors in our diabetic population. We hope our colleagues in Japan, Italy and Spain release their data soon and we can draw more concise conclusions.

Until then, given the current circumstances we need immediate action from our medical societies to make appropriate guidelines and protocols for us in real-time despite the limited available evidence, especially when there is an anticipation of limited hospital resources and strain of healthcare workers. Should we change and modify our current practice temporarily to meet the demands? General endocrinologists, primary care providers, patients and caregivers all need guidance to be able to manage diabetes during this pandemic in real-time.

Funding

None.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

[1] Wang A, Zhao W, Xu Z, Gu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract 2020;13:108118. https://doi.org/10.1016/j.diabres.2020.108118.

[2] Schuetz P, Castro P, Shapiro NI. Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes Care 2011;34(3):771–8. https://doi.org/10.2327/dc10-1185.

[3] Schuetz P, Jones AE, Howell MD, Trzeciak S, Ngo L, Younger JG, Aird W, Shapiro NI. Diabetes is not associated with increased mortality in emergency department patients with sepsis. Ann Emerg Med 2011;58(5):438–44.

[4] Vincent JL, Presler JC, Sprung CL, Moreno R, Sakr Y. Insulin-treated diabetes is not associated with increased mortality in critically ill patients. Crit Care 2010;14:R12.

[5] Stegenga ME, Vincent JL, Vail GM, et al. Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med 2009;38:539–45.

[6] Esper AM, Moss M, Martin GS. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Crit Care 2009;13:R18.

[7] Moss M, Guidot DM, Steinberg KP, et al. Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med 2000;28:2187–92.

[8] Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Sørensen HT, Schønheyder HC. Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care 2004;27:70–6.

[9] Graham BB, Keniston A, Gajic O, Trillo Alvarez CA, Medvedev S, Douglas IS. Diabetes mellitus does not adversely affect outcomes from a critical illness. Crit Care Med 2010;38:16–24.

[10] Peake SL, Moran JL, Ghelani DR, Lloyd AJ, Walker MJ. The effect of obesity on 12-month survival following admission to intensive care: a prospective study. Crit Care Med 2006;34:2929–39.

[11] van den Berge G, Wouters P, Weebers E, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359–67.

[12] Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773–8.

[13] Van den Berge G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449–61.

[14] Brunkhorst FM, Engel C, Bloos F, et al. German Competence Network Sepsis (SepNet) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125–39.

[15] Finfer S, Chittock DR, Su SY, et al. NICE-SUGAR Study Investigators Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283–97.

[16] Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Schønheyder HC, Sørensen HT. Risk of community-acquired pneumococcal bacteremia in patients with diabetes: a population-based case-control study. Diabetes Care 2004;27:1143–7.

[17] Akirov A, Grissman A, Shochat T, Shimon I. Mortality among hospitalized patients with hypoglycemia: insulin related and noninsulin related. J Clin Endocrinol Metab 2017;102 (2):416–24.